Sermorelin — Research Overview
Chemical Name: Growth hormone-releasing hormone (1-29) NH2 acetate — the 1-29 N-terminal fragment of human GHRH Also Known As: Sermorelin, GRF 1-29, GHRH(1-29)-NH2, sermorelin acetate Brand Name (Historical): Geref, Geref Diagnostic (Serono Laboratories) Amino Acid Sequence (29-aa): Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 Structure: C-terminal amidated linear 29-amino acid polypeptide representing residues 1 through 29 of the 44-amino acid native human growth hormone-releasing hormone (GHRH). Residues 1-29 constitute the shortest fully functional fragment of GHRH that retains complete biological activity at the GHRH receptor. The C-terminus is amidated (-NH2) rather than carrying a free carboxyl, which improves metabolic stability compared to non-amidated forms. Relationship to GHRH: Human GHRH is a 44-amino acid hypothalamic peptide. The essential pharmacophore — the minimum sequence required for full GHRH receptor activation — is contained within the first 29 amino acids. Residues 30-44 are dispensable for receptor activity, making sermorelin (1-29) functionally equivalent to the complete GHRH molecule at the receptor level. FDA Regulatory History: FDA-approved in 1990 as a diagnostic agent for GH reserve assessment. FDA-approved in 1997 (NDA) as Geref for treatment of idiopathic growth hormone deficiency in children with growth failure. Discontinued by the manufacturer Serono in 2008 for commercial manufacturing reasons — not for safety reasons. No regulatory action, market withdrawal for safety, or recall was involved in the discontinuation. Sermorelin is currently classified as a discontinued drug product by the FDA but remains available through licensed compounding pharmacies with a valid prescription. Relationship to Other GHRH Analogs in This Catalog: Sermorelin (1-29, unmodified), CJC-1295 (modified 1-29 fragment with DAC for half-life extension), and Tesamorelin (44-aa full-length modified GHRH, FDA-approved for HIV lipodystrophy) all act on the same GHRH receptor but have different pharmacokinetic profiles and clinical applications. Sermorelin produces the most physiologically natural acute pulsatile GH pulse; tesamorelin acts for longer due to structural modifications; CJC-1295 with DAC provides extended continuous GH elevation. WADA Status: Growth hormone releasing factors are prohibited under S2 (peptide hormones, growth factors, related substances, and mimetics) Category: GHRH analog / pituitary GH secretagogue / GHRHR agonist / former FDA-approved pharmaceutical / compounded prescription drug (current status in US)
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption outside of any applicable prescription compounded pharmaceutical context. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Sermorelin?
Sermorelin is a synthetic 29-amino acid polypeptide representing the biologically active N-terminal fragment of human growth hormone-releasing hormone — the hypothalamic neuropeptide that drives the pulsatile secretion of growth hormone from the anterior pituitary gland. It is the shortest GHRH fragment that retains the full biological activity of the complete 44-amino acid molecule at the GHRH receptor, making it a compact and pharmacologically efficient tool for studying and modulating the growth hormone axis.
Sermorelin’s regulatory history distinguishes it from most research peptides in this catalog. It received FDA approval in 1990 as a diagnostic agent for assessment of pituitary GH reserve and in 1997 as a therapeutic for pediatric growth hormone deficiency — backed by controlled clinical trials demonstrating efficacy and safety in GH-deficient children. The 2008 discontinuation was a commercial manufacturing decision by Serono, not a regulatory action precipitated by safety concerns. This history means that the sermorelin safety profile is characterized by regulated clinical trial data rather than only preclinical research, and that its mechanistic effects on the pituitary and growth hormone axis are among the best characterized of any compound in this catalog.
The central pharmacological distinction of sermorelin from direct recombinant human growth hormone (rhGH) replacement is mechanistically important and defines its research and clinical significance. Exogenous rhGH bypasses the hypothalamic-pituitary regulatory axis entirely — delivering preformed growth hormone directly into circulation, producing supraphysiological GH concentrations, suppressing endogenous GHRH production through negative feedback, reducing pituitary sensitivity over time, and creating pharmacokinetic peaks and troughs that do not replicate physiological pulsatile GH secretion. Sermorelin, by contrast, acts at the GHRH receptor on pituitary somatotroph cells — stimulating the gland’s own GH production and secretion within a framework that retains the body’s natural regulatory architecture. Because somatostatin (the hypothalamic GH-inhibitory hormone) continues to modulate pituitary responses to sermorelin, the normal negative feedback that prevents GH excess remains intact, making overdose of the physiological GH axis pharmacologically very difficult.
The GH Axis — Biology and Age-Related Decline
Understanding sermorelin requires understanding the hypothalamic-pituitary-GH axis and how it changes with age.
The GH secretory axis is a three-component system: the hypothalamus produces GHRH (stimulatory) and somatostatin (inhibitory) in alternating pulses; the anterior pituitary somatotroph cells respond to these pulsatile inputs by secreting GH in bursts, predominantly during slow-wave (deep) sleep; and the liver responds to GH by producing insulin-like growth factor-1 (IGF-1), which mediates many of GH’s peripheral anabolic and metabolic effects while providing negative feedback that modulates GHRH and somatostatin release.
This pulsatile architecture is biologically essential. Pulsatile GH exposure — not continuous elevation — is required for optimal anabolic signaling, maintenance of GH receptor sensitivity, and the metabolic effects of the GH/IGF-1 axis. Continuous supraphysiological GH (as occurs with exogenous rhGH injection) desensitizes GH receptors and impairs the downstream signaling that pulsatile GH optimizes.
GH secretion declines substantially with age — approximately 14% per decade after peak GH production in young adulthood. This decline in the somatotropic axis has been mechanistically characterized: the primary defect is not in the pituitary’s capacity to produce GH, but in the amplitude and frequency of GHRH pulse signals reaching the pituitary from the hypothalamus. Somatostatin tone simultaneously increases with aging, further suppressing GH release. The pituitary remains responsive to exogenous GHRH — demonstrated by the fact that sermorelin produces robust GH responses in aged individuals — but no longer receives adequate endogenous GHRH stimulation to maintain youthful GH output. This means that sermorelin does not overcome a pituitary defect; it restores the stimulatory signal that the aging hypothalamus fails to deliver adequately.
Research in the GH axis and aging suggests that the progressive decline in GHRH pulse amplitude represents one of the earliest deteriorations of the hypothalamic neuroendocrine system. Because the pituitary remains responsive, strategies that restore GHRH stimulation — including sermorelin — can substantially recover GH production and maintain pituitary somatotroph function, potentially slowing the cascade of hypophyseal hormone changes that accompany aging.
Mechanism of Action
GHRH receptor (GHRHR) agonism: Sermorelin binds to the GHRH receptor — a G-protein coupled receptor (specifically Gs-coupled) expressed on the surface of somatotroph cells in the anterior pituitary. This binding activates adenylyl cyclase through Gs protein coupling, elevating intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A, which phosphorylates CREB (cAMP response element binding protein), driving transcription of the GH gene and other somatotroph-specific genes. The net result is both enhanced GH synthesis and acute GH secretion from somatotroph granules into the portal circulation.
Pulsatile physiological GH release: Because sermorelin acts through the endogenous regulatory pathway rather than bypassing it, GH secretion following sermorelin administration reflects the body’s normal regulatory constraints. Somatostatin continues to exert its inhibitory influence on pituitary responsiveness, creating natural pulsatile GH secretion patterns rather than sustained flat elevation. This pulsatility is the pharmacological basis for sermorelin’s preservation of GH receptor sensitivity and its lower risk of the adverse effects associated with continuous supraphysiological GH exposure (insulin resistance, fluid retention, acromegaly features). The pharmacokinetic data confirm: after subcutaneous sermorelin administration, peak GH concentrations are reached within 20-60 minutes, and sermorelin itself is rapidly cleared with a plasma half-life of approximately 11-12 minutes — short enough to allow the GH pulse to complete and somatostatin to re-establish inhibitory tone, preventing sustained unphysiological elevation.
IGF-1 production: GH released from the pituitary in response to sermorelin travels to the liver and other peripheral tissues, where it binds to GH receptors and stimulates IGF-1 production. IGF-1 circulates systemically and mediates many of GH’s anabolic effects — including lean mass accretion, fat mobilization, bone density maintenance, protein synthesis, and tissue repair. IGF-1 is the primary biomarker used to assess the adequacy of GH axis function and to monitor sermorelin response in clinical settings.
Pituitary gene transcription enhancement: Beyond acute GH secretion, sermorelin stimulates the pituitary to enhance GH gene transcription — increasing the somatotroph’s biosynthetic capacity for GH over time. This GH gene transcription effect, documented in pituitary cell studies, means that sermorelin’s impact extends beyond triggering acute GH release to sustaining or restoring the pituitary’s reserve capacity — a potential mechanism for what has been described as “pituitary recrudescence.” This is the proposed basis for the observation that sustained sermorelin therapy may help maintain hypothalamic-pituitary function during aging in a way that simple GH replacement does not.
Receptor selectivity: Intravenous and subcutaneous sermorelin specifically stimulate GH secretion without significant change in prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), insulin, cortisol, blood glucose, glucagon, or thyroid hormone levels — establishing high specificity for the GHRH receptor/somatotroph pathway among pituitary hormone systems. This selectivity distinguishes sermorelin’s pharmacology from broader pituitary stimulants and confirms that its clinical effects are attributable to GH axis activation rather than multi-hormonal disruption.
Published Research
Study 1 — Foundational Clinical Trial: Once-Daily Sermorelin Accelerates Growth in GH-Deficient Children (Year One)
Authors: Thorner MO et al. (Geref International Study Group) Year: 1996 Journal: Journal of Clinical Endocrinology and Metabolism Referenced via: JCEM 1996;81(3):1189 (Geref International Study Group)
This was the primary pivotal clinical trial that established sermorelin’s efficacy for treatment of pediatric growth hormone deficiency — the evidence base that supported the 1997 FDA approval for therapeutic use.
Children with confirmed idiopathic growth hormone deficiency received once-daily subcutaneous sermorelin at 30 micrograms/kg bodyweight administered at bedtime, taking advantage of the natural nocturnal GH pulse to maximize pituitary responsiveness.
Height velocity — the primary efficacy endpoint — significantly increased in 74% of GH-deficient children within 6 months of sermorelin treatment. Significant increases in height velocity were maintained through 12 months.
Sermorelin was well tolerated across the study population. The most commonly reported adverse events were transient facial flushing and injection site reactions — consistent with the known pharmacological effects of GHRH receptor activation and standard subcutaneous injection reactions. No serious drug-related adverse events were observed.
This trial established the foundational efficacy and safety profile that justified therapeutic FDA approval and that remains the primary controlled human clinical evidence for sermorelin’s GH-stimulating activity in documented GH-deficient subjects.
Study 2 — Clinical Review: Sermorelin in Diagnosis and Treatment of Pediatric GH Deficiency
Authors: Prakash A, Goa KL Year: 1999 Journal: BioDrugs PMID: 18031173 Full text: https://pubmed.ncbi.nlm.nih.gov/18031173/
This comprehensive clinical review synthesized the available evidence for sermorelin’s diagnostic and therapeutic utility in pediatric growth hormone deficiency — providing the most thorough published evaluation of the clinical evidence base from the FDA-approval era.
Sermorelin at 1 microgram/kg intravenously represents a rapid and relatively specific diagnostic test for growth hormone deficiency — producing fewer false positive GH responses in children without true GH deficiency compared to other provocative tests (insulin tolerance test, arginine, clonidine).
The combination of intravenous sermorelin plus arginine was identified as potentially more specific than sermorelin alone — a test combination that has been used in adult GH reserve assessment.
Once-daily subcutaneous sermorelin at 30 micrograms/kg bodyweight administered at bedtime produced significant and sustained height velocity increases. Children with slow growth, shorter stature, and delayed bone age showed particularly favorable responses — establishing baseline characteristics predictive of good sermorelin response.
Data in a subset of children demonstrated sustained treatment effect at 36 months — confirming that sermorelin’s growth-promoting effects are maintained with continued treatment rather than showing tachyphylaxis.
The review noted that sermorelin produced less height velocity gain than directly-dosed somatropin (recombinant GH) — an expected finding, since sermorelin works by stimulating the child’s own GH production rather than directly replacing GH. This difference explained why sermorelin failed commercially as a pediatric GH treatment despite safety advantages — GH-deficient children require higher GH concentrations than their own pituitary can produce even under optimal GHRH stimulation, whereas adults with age-related GH decline retain pituitary reserve sufficient to benefit from GHRH stimulation.
Study 3 — GHRH Analog in Older Adults: Somatotropic Axis Activation, Body Composition, and Cognition
Authors: Merriam GR, Buchner DM et al. (University of Washington); additionally: Vitiello MV, Schwartz RS, Moe KE, Mazzoni G, Merriam GR (Treating Age-Related Changes in Somatotrophic Hormones, Sleep, and Cognition) Year: 1997 (endocrine journal) and subsequent; full trial data published via 2001-2006 reports Referenced via: Merriam GR et al., Endocrine. 1997; and PMC3181657
This research program at the University of Washington directly examined sermorelin (GHRH acetate, Geref) effects in older adults — the most directly relevant human evidence for sermorelin’s application in the context of age-related GH decline.
Male subjects in the trial doubled their 24-hour GH secretion and experienced a 40% rise in IGF-1 levels with GHRH treatment. Premenopausal or non-estrogen-replacing postmenopausal women experienced similar 30% IGF-1 increases. Women on oral estrogen replacement showed blunted IGF-1 responses despite vigorous GH increases, suggesting oral estrogen-induced hepatic GH resistance — an important finding for clinical translation.
Sermorelin administration produced a large acute GH burst immediately following each evening injection. This confirmed robust pituitary responsiveness to GHRH stimulation in aged subjects — directly demonstrating that the hypothalamic GHRH pulse deficit of aging, rather than pituitary failure, is the primary mechanism of age-related GH decline. The pituitary remained fully responsive to exogenous GHRH; it simply was not receiving adequate endogenous GHRH pulses.
Body composition improved: once-daily GHRH treatment produced significant increases in lean body mass and decreases in fat mass in older male subjects. These anabolic and lipolytic effects represent the core metabolic benefits of restored GH/IGF-1 axis activity in aged individuals.
A 6-month sermorelin treatment study in 89 elderly adults found significant improvement on several cognitive assessments, particularly those involving problem solving, psychomotor processing speed, and working memory. Higher GH levels correlated with higher Wechsler Adult Intelligence Scale performance IQ scores. Greater IGF-1 increases correlated with higher verbal fluency scores — directly linking the somatotropic axis restoration to cognitive benefits.
Skin thickness increased in both men and women — a marker of GH-dependent tissue effects.
Study 4 — Endocrine and Metabolic Effects of GHRH Analog in Age-Advanced Adults
Authors: Referenced via PMID 9141536 (Nle27-GHRH analog study in age-advanced men and women) Year: 1997 Journal: Journal of Clinical Endocrinology and Metabolism PMID: 9141536 Full text: https://pubmed.ncbi.nlm.nih.gov/9141536/
This study of a GHRH analog administered nightly for 4 months in age-advanced men and women provided one of the most comprehensive metabolic characterizations of GHRH agonism in aged subjects.
Nightly GHRH analog administration activated the somatotropic axis in both men and women — confirming that the aging pituitary retains substantial GHRH receptor-mediated GH release capacity when adequately stimulated.
Lean body mass increases, reduced fat mass, increased skin thickness, improved insulin sensitivity, improved general well-being (P less than 0.05 in men), and improved libido (P less than 0.01 in men) were documented. These metabolic and quality-of-life benefits mirror those associated with GH restoration in younger GH-deficient adults.
Sleep quality was unaffected in both genders — an important neutral finding, as sleep architecture is a common clinical concern with GH axis manipulation. The expected GH secretion peak during slow-wave sleep was not disrupted.
The only adverse side effect was transient hyperlipidemia, which resolved by the end of the study period — a mild and reversible effect.
The authors concluded that GHRH analog administration induced anabolic effects favoring men more than women, with the gender difference attributed to the oral estrogen-related GH resistance observed in postmenopausal women on estrogen replacement therapy.
Study 5 — Clinical Review: Sermorelin as an Alternative to rhGH for Adult GH Insufficiency
Authors: Walker RF Year: 2006 Journal: Clinical Interventions in Aging (Dove Press) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
This clinical review is the most widely cited publication directly arguing the case for sermorelin as a preferable alternative to direct GH replacement in aging adults — synthesizing the pharmacological, physiological, and regulatory arguments for this approach.
The review articulated the paradox of sermorelin’s commercial failure in pediatrics: it failed because GH-deficient children need higher GH concentrations than stimulation of their own pituitary can achieve. This is precisely why sermorelin is a better fit for aging adults, whose pituitary retains GH production capacity but no longer receives adequate endogenous GHRH stimulation. In aging, the primary deficit is in hypothalamic GHRH amplitude — sermorelin restores this signal and the pituitary responds normally.
The physiological and clinical advantages of sermorelin over rhGH were explicitly enumerated: effects are regulated by negative feedback via somatostatin preventing overdose; GH is released in bursts mimicking natural hormone rhythms rather than the constant supraphysiological levels produced by rhGH injections; sermorelin avoids tachyphylaxis through pulsatile signaling; sermorelin stimulates GH gene transcription thereby maintaining rather than suppressing pituitary function; and the off-label legal landscape for sermorelin is less restrictive than for rhGH, which is federally restricted to specific approved indications in adults.
The review identified pituitary recrudescence as a key long-term benefit — the concept that sustained GHRH receptor stimulation maintains somatotroph function and helps slow the progressive decline in pituitary hormone production that characterizes aging. This pituitary-maintaining effect is not available from exogenous GH replacement, which suppresses rather than supports endogenous pituitary function.
Sermorelin vs Rhgh — The Central Pharmacological Comparison
The comparison between sermorelin and recombinant human growth hormone (rhGH) is the most pharmacologically important distinction in this profile and defines sermorelin’s specific research significance.
Recombinant human GH (rhGH / somatropin) — Direct exogenous GH replacement. Bypasses the entire hypothalamic-pituitary regulatory axis. Delivers preformed GH directly into circulation independent of pituitary function. Suppresses endogenous GHRH production through negative feedback. Creates supraphysiological GH peaks that the normal physiological system would never produce. Requires continuous administration to maintain effects. Restricted by federal law in adults to specific approved indications (GH deficiency diagnosed pursuant to accepted guidelines, and HIV lipodystrophy). Associated with risks including insulin resistance, fluid retention, carpal tunnel syndrome, potential IGF-1-mediated cancer risk in long-term high-dose use, and growth plate stimulation in children.
Sermorelin — Acts upstream of the pituitary at the GHRH receptor. Stimulates the body’s own GH synthesis and secretion. Preserves pituitary involvement and therefore somatostatin-mediated negative feedback. Maintains physiological pulsatile GH secretion patterns. Supports rather than suppresses hypothalamic-pituitary axis function. Requires adequate pituitary reserve to work — does not function in patients with destroyed pituitary somatotrophs. Pharmacologically very difficult to overdose because the somatostatin feedback mechanism remains intact. Less potent in absolute GH elevation than rhGH but physiologically more appropriate. Off-label adult use through compounding pharmacies is not prohibited by federal law.
The pharmacological distinction is not merely theoretical — it is the reason why sermorelin produces GH effects that more closely mirror the young adult physiological pattern, while rhGH creates an artificial hormonal environment that the body was never designed to experience.
Sermorelin and the GHRH Analog Family
Sermorelin (1-29) is the simplest and shortest member of the GHRH analog family. Its sibling compounds in this catalog include CJC-1295 (a modified 1-29 fragment designed for extended half-life) and Tesamorelin (a 44-amino acid full-length GHRH analog with structural modifications, FDA-approved for HIV-associated lipodystrophy). All three act on the GHRH receptor but with different pharmacokinetic profiles.
Sermorelin produces a single acute GH pulse corresponding to its 11-12 minute plasma half-life. CJC-1295 without DAC (Drug Affinity Complex) produces a similar single pulse with slightly extended duration; CJC-1295 with DAC produces sustained GH elevation for days through covalent albumin binding. Tesamorelin, modified for stability against DPP-4 enzymatic degradation, produces a more sustained GH stimulation than native sermorelin while retaining full GHRH receptor activity and has completed Phase 3 clinical trials and received FDA approval for its specific indication.
For research protocols where brief acute physiological GH pulses are the experimental objective, sermorelin is the most appropriate tool. For protocols requiring extended GH axis stimulation, CJC-1295 or tesamorelin may be more appropriate. The choice between GHRH analogs is pharmacokinetically driven by the research question.
Age-Related GH Decline — Research Context
GH secretion declines approximately 14% per decade after peak in young adulthood. By age 60, many individuals have IGF-1 levels in the range associated with adult-onset GH deficiency diagnosed in younger patients. This age-related somatopenia is mechanistically characterized as a hypothalamic GHRH pulse amplitude defect rather than primary pituitary failure — the pituitary remains responsive to GHRH, as demonstrated by sermorelin response studies in elderly subjects.
Correlates of reduced GH/IGF-1 with aging include increased visceral adiposity, reduced lean body mass, reduced bone mineral density, impaired recovery from injury and exercise, reduced slow-wave sleep, and cognitive changes in certain domains. Whether these correlates represent consequences of GH decline or parallel processes of aging, and whether restoring GH/IGF-1 through secretagogue therapy meaningfully addresses them, are active and unresolved research questions that sermorelin studies are designed to address.
Safety Profile and Considerations
Sermorelin’s safety profile from the regulated FDA clinical trial period is favorable. The most common adverse events in clinical studies were transient facial flushing shortly after injection (a pharmacological consequence of GHRH receptor activation in vascular smooth muscle) and injection site reactions (redness, pain, swelling) — both mild and transient.
Selective GH axis stimulation was confirmed: sermorelin does not significantly affect prolactin, LH, FSH, cortisol, insulin, blood glucose, glucagon, or thyroid hormones at clinical doses — establishing endocrine selectivity.
Clinically relevant considerations for extended use include: insulin resistance (GH antagonizes insulin action; blood glucose monitoring is advisable in predisposed individuals), fluid retention and potential carpal tunnel symptoms at higher doses, thyroid function changes (GH stimulation can unmask subclinical hypothyroidism), and the theoretical IGF-1/cancer relationship that applies to any GH axis-elevating intervention.
Sermorelin is contraindicated in active malignancy (GH and IGF-1 promote cellular proliferation) and should not be used by children whose epiphyseal plates have not yet fused, as in clinical GH therapy (growth plate stimulation remains active).
Current Status and Compounding Availability
Sermorelin is classified as a discontinued drug product by the FDA following Serono’s 2008 commercial discontinuation. It is not available as an FDA-approved branded pharmaceutical in the United States. It remains available through licensed compounding pharmacies for prescription by physicians in the United States. Compounded sermorelin is not subject to the same FDA oversight as the original branded product. This regulatory status places sermorelin in a distinctive position — it has more historical clinical validation than most compounded compounds due to its prior FDA approval, but its current compounded form is not subject to FDA review for quality, potency, or sterility in the same way an approved pharmaceutical would be.
As a research compound, sermorelin is used for in vitro and in vivo investigation of the GHRH receptor, GH axis pharmacology, and somatotropic axis aging biology.
Reconstitution Note
Sermorelin is supplied as lyophilized powder. Bacteriostatic water is the standard reconstitution solvent for multi-dose research preparations. Sermorelin dissolves readily in aqueous solution. Protect from light. Note that the peptide contains methionine residue 27 which is susceptible to oxidation — minimize exposure to air during reconstitution and use. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light. Avoid repeated freeze-thaw cycles. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration (particularly yellow-brown coloration indicating methionine oxidation), or signs of degradation.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Sermorelin product page: https://roguecompounds.com/product/sermorelin/